Head & Neck Cancers | Specialty

Enter PD-1 Inhibitors; A New Paradigm for HNSCC

November 7th 2016

Unmet Needs in Recurrent HNSCC

November 7th 2016

Debates Surrounding Induction Chemotherapy in HNSCC

November 7th 2016

Appropriate Use of Chemotherapy in HNSCC

November 7th 2016

Surgery and Radiotherapy for HNSCC

November 7th 2016

Long-Term Toxicity in HNSCC

November 7th 2016

Goals of Therapy for HNSCC

November 7th 2016

Locoregionally Advanced HNSCC

November 7th 2016

Factors Influencing Treatment Decisions for HNSCC

November 7th 2016

HPV Testing in HNSCC

November 7th 2016

Prognostic Factors for HNSCC

November 7th 2016

Underlying Biology of HPV-Positive and -Negative HNSCC

November 7th 2016

Speed Critical With Anaplastic Thyroid Cancer Diagnosis, Treatment

November 3rd 2016

Enrolling clinical trials can be a long process, especially in rare diseases with limited patient populations. This is a particularly significant issue for patients with anaplastic thyroid cancer, an extremely rare and aggressive disease.

Jena D. French on Anti-PD-1/Lenvatinib Combo in Differentiated Thyroid Cancer

November 3rd 2016

Jena D. French, PhD, instructor of medicine, division of endocrinology, metabolism and diabetes, Anschutz Medical Campus, University of Colorado, discusses the potential for immunotherapy combinations with lenvatinib in differentiated thyroid cancer.

Immunotherapy Potentially Promising for Treatment of ATC

October 21st 2016

Given the poor prognoses often seen in patients with anaplastic thyroid cancer, researchers are seeking novel therapies that may hold more promise than surgery or radiation.

Expert Emphasizes Lack of Treatment Options for Medullary Thyroid Cancer

October 20th 2016

Though some patients with medullary thyroid cancer can live with their disease without progression for long periods of time, the majority will eventually enter a phase in which their cancer becomes much more aggressive.

Bridgett Harr on Managing Long-term Side Effects in Head and Neck Cancer

October 19th 2016

Bridgett Harr, CNP, radiation oncology, Cleveland Clinic, discusses survivorship and managing long-term side effects in head and neck cancer.

Dr. Cohen on Biomarker Testing in Head and Neck Cancer

October 15th 2016

Ezra Cohen, MD, associate director, Moores Cancer Center, professor of Medicine, University of California, San Diego Health System, discusses biomarker testing in patients with head and neck cancer.

No PFS Benefit in Recurrent Head and Neck Cancer With Addition of Immunotherapy

October 12th 2016

Adding a Toll-like receptor 8 agonist to standard care for patients with recurrent or metastatic squamous cell carcinoma of the head and neck failed to improve progression-free survival.

Dr. Burtness on Immunotherapy and Chemotherapy in Head and Neck Cancer

October 12th 2016

Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, discusses the potential benefits of using immunotherapy and chemotherapy together in head and neck cancer.